PharVision Advisers’s Vertiv VRT Stock Holding History

PharVision Advisers’s Portfolio VRT Stock Details VRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,238	Closed	-$639K	–	1030
2025 Q3	$639K	Buy	+4,238	New	+$565K	0.36%	7

Other funds holding VRT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

PharVision Advisers's VRT Position: Q4 2025 in Review

PharVision Advisers sold out of Vertiv (VRT) in Q4 2025, closing a stake of 4,238 shares — an estimated $639K sold.

PharVision Advisers first reported a position in VRT in Q3 2025 and held it in 1 quarter. The position peaked at $639K in Q3 2025. 1,611 funds tracked by Wall St. Rank hold VRT as of Q4 2025.

PharVision Advisers reported no remaining Vertiv position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 4,238 Vertiv shares in Q4 2025, an estimated $639K.
PharVision Advisers first reported a position in Vertiv in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Vertiv position peaked at $639K in Q3 2025.
1,611 funds tracked by Wall St. Rank held Vertiv as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.